A Cross Sectional Survey of Factors Related to Cannabis Use as a Sleep Aid Among Canadian Cancer Survivors.

IF 2.2 3区医学 Q3 CLINICAL NEUROLOGY

Behavioral Sleep Medicine Pub Date : 2024-09-01 Epub Date: 2024-05-28 DOI:10.1080/15402002.2024.2361015

Rachel M Lee, Jennifer Donnan, Nick Harris, Sheila N Garland

{"title":"A Cross Sectional Survey of Factors Related to Cannabis Use as a Sleep Aid Among Canadian Cancer Survivors.","authors":"Rachel M Lee, Jennifer Donnan, Nick Harris, Sheila N Garland","doi":"10.1080/15402002.2024.2361015","DOIUrl":null,"url":null,"abstract":"Objectives: Poor sleep is a common side effect of cancer. Cannabis is increasingly used to manage cancer treatment-related symptoms, including sleep. This study investigated factors related to cannabis use for sleep among Canadian cancer survivors.Method: Adult Canadian cancer survivors (N = 940) were recruited via the Angus Reid Institute and completed an online, cross-sectional survey. Univariate and multiple binomial logistic regression models identified factors associated with cannabis use for sleep.Results: Of the participants (Mage = 64.5 yrs; Women = 51.1%; White = 92.9%), 25.1% (n = 236) currently use cannabis for sleep. Participants were at greater odds of using cannabis for sleep if they identified as a gender other than man or woman (AOR = 11.132), were diagnosed with multiple medical conditions (2:AOR = 1.988; 3+:AOR = 1.902), two psychological conditions (AOR = 2.171), multiple sleep disorders (AOR = 2.338), insomnia (AOR = 1.942), bone (AOR = 6.535), gastrointestinal (AOR = 4.307), genitourinary (AOR = 2.586), hematological (AOR = 4.739), or an unlisted cancer (AOR = 3.470), received hormone therapy only (AOR = 3.054), drink heavily (AOR = 2.748), or had mild insomnia (AOR = 1.828). Older participants (AOR=.972) and those with sleep apnea were less likely to use cannabis for sleep (AOR=.560).Conclusion: Given its prevalence, research is needed to understand how factors associated with cannabis use as a sleep aid among Canadian cancer survivors may influence its use and effectiveness and whether these factors are barriers to accessing evidence-based treatments.","PeriodicalId":55393,"journal":{"name":"Behavioral Sleep Medicine","volume":" ","pages":"754-769"},"PeriodicalIF":2.2000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Behavioral Sleep Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/15402002.2024.2361015","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/28 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Poor sleep is a common side effect of cancer. Cannabis is increasingly used to manage cancer treatment-related symptoms, including sleep. This study investigated factors related to cannabis use for sleep among Canadian cancer survivors.

Method: Adult Canadian cancer survivors (N = 940) were recruited via the Angus Reid Institute and completed an online, cross-sectional survey. Univariate and multiple binomial logistic regression models identified factors associated with cannabis use for sleep.

Results: Of the participants (M_age = 64.5 yrs; Women = 51.1%; White = 92.9%), 25.1% (n = 236) currently use cannabis for sleep. Participants were at greater odds of using cannabis for sleep if they identified as a gender other than man or woman (AOR = 11.132), were diagnosed with multiple medical conditions (2:AOR = 1.988; 3+:AOR = 1.902), two psychological conditions (AOR = 2.171), multiple sleep disorders (AOR = 2.338), insomnia (AOR = 1.942), bone (AOR = 6.535), gastrointestinal (AOR = 4.307), genitourinary (AOR = 2.586), hematological (AOR = 4.739), or an unlisted cancer (AOR = 3.470), received hormone therapy only (AOR = 3.054), drink heavily (AOR = 2.748), or had mild insomnia (AOR = 1.828). Older participants (AOR=.972) and those with sleep apnea were less likely to use cannabis for sleep (AOR=.560).

Conclusion: Given its prevalence, research is needed to understand how factors associated with cannabis use as a sleep aid among Canadian cancer survivors may influence its use and effectiveness and whether these factors are barriers to accessing evidence-based treatments.

查看原文本刊更多论文

对加拿大癌症幸存者使用大麻作为睡眠辅助工具相关因素的横断面调查》（A Cross Sectional Survey of Factors related to Cannabis Use as a Sleep Aid Among Canadian Cancer Survivors）。

目的：睡眠不佳是癌症的常见副作用。越来越多的人使用大麻来控制与癌症治疗相关的症状，包括睡眠。本研究调查了加拿大癌症幸存者使用大麻促进睡眠的相关因素：通过安格斯-里德研究所（Angus Reid Institute）招募了加拿大成年癌症幸存者（940 人），并完成了一项在线横断面调查。单变量和多重二项式逻辑回归模型确定了与使用大麻促进睡眠有关的因素：在参与者（年龄 = 64.5 岁；女性 = 51.1%；白人 = 92.9%）中，25.1%（n = 236）的人目前使用大麻促进睡眠。如果参与者的性别不是男性或女性（AOR = 11.132）、被诊断患有多种疾病（2:AOR = 1.988；3+:AOR = 1.902）、患有两种心理疾病（AOR = 2.171）、患有多种睡眠障碍（AOR = 2.338）、失眠（AOR = 1.942）、骨骼（AOR = 6.535）、胃肠道（AOR = 4.307）、泌尿生殖系统（AOR = 2.586）、血液系统（AOR = 4.739）或未列出的癌症（AOR = 3.470）、仅接受激素治疗（AOR = 3.054）、酗酒（AOR = 2.748）或轻度失眠（AOR = 1.828）。年龄较大的参与者（AOR=.972）和患有睡眠呼吸暂停的参与者使用大麻促进睡眠的可能性较小（AOR=.560）：鉴于大麻的普遍性，需要开展研究以了解在加拿大癌症幸存者中使用大麻作为助眠药物的相关因素会如何影响其使用和效果，以及这些因素是否会成为获得循证治疗的障碍。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Behavioral Sleep Medicine CLINICAL NEUROLOGY-PSYCHIATRY

CiteScore

7.20

自引率

3.20%

发文量

审稿时长

>12 weeks

期刊介绍： Behavioral Sleep Medicine addresses behavioral dimensions of normal and abnormal sleep mechanisms and the prevention, assessment, and treatment of sleep disorders and associated behavioral and emotional problems. Standards for interventions acceptable to this journal are guided by established principles of behavior change. Intending to serve as the intellectual home for the application of behavioral/cognitive science to the study of normal and disordered sleep, the journal paints a broad stroke across the behavioral sleep medicine landscape. Its content includes scholarly investigation of such areas as normal sleep experience, insomnia, the relation of daytime functioning to sleep, parasomnias, circadian rhythm disorders, treatment adherence, pediatrics, and geriatrics. Multidisciplinary approaches are particularly welcome. The journal’ domain encompasses human basic, applied, and clinical outcome research. Behavioral Sleep Medicine also embraces methodological diversity, spanning innovative case studies, quasi-experimentation, randomized trials, epidemiology, and critical reviews.